Treatment challenges in adult female acne and future directions

References

• Zeichner JA, Baldwin HE, Cook-Bolden FE, et al. Emerging issues in adult female acne. J Clin Aesthet Dermatol. 2017;10(1):37–46.
   PubMedGoogle Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2163–2196.
   PubMed Web of Science ®Google Scholar
• Lynn DD, Umari T, Dunnick CA, et al. The epidemiology of acne vulgaris in late adolescence. Adolesc Health Med Ther. 2016;7:13–25.
   PubMed Web of Science ®Google Scholar
• Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41(4):577–580.
   PubMed Web of Science ®Google Scholar
• Poli F, Dréno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol. 2001;15:541–545.
   PubMed Web of Science ®Google Scholar
• Rocha MA, Bagatin E. Adult-onset acne: prevalence, impact, and management challenges. Clin Cosmet Invest Dermatol. 2018;11:59–69.
   PubMed Web of Science ®Google Scholar
• Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58(1):56–59.
   PubMed Web of Science ®Google Scholar
• Dréno B, Layton A, Zouboulis CC, et al. Adult female acne: a new paradigm. J Eur Acad Dermatol Venereol. 2013;27(9):1063–1070.
   PubMed Web of Science ®Google Scholar
• Goulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol. 1999;141(2):297–300.
   PubMed Web of Science ®Google Scholar
• Dréno B, Thiboutot D, Layton AM, et al. Large-scale international study enhances understanding of an emerging acne population: adult females. J Eur Acad Dermatol Venereol. 2015;29(6):1096–1106.
   PubMed Web of Science ®Google Scholar
• Albuquerque RGR, Rocha MAD, Bagatin E, et al. Could adult female acne be associated with modern life? Arch Dermatol Res. 2014;306(8):683–688.
   PubMed Web of Science ®Google Scholar
• Romanska-Gocka K, Wozniak M, Kaczmarek-Skamira E, et al. The possible role of diet in the pathogenesis of adult female acne. Postepy Dermatol Alergol. 2016;33(6):416–420.
   PubMed Web of Science ®Google Scholar
• Claudel JP, Auffret N, Leccia MT, et al. Acne and nutrition: hypotheses, myths and facts. J Eur Acad Dermatol Venereol. 2018;32(10):1631–1637.
   PubMed Web of Science ®Google Scholar
• Penso L, Touvier M, Deschasaux M, et al. Association between adult acne and dietary behaviors. Findings from the NutriNet-Santé prospective cohort study. JAMA Dermatol. 2020;156(8):854–862.
   PubMed Web of Science ®Google Scholar
• Di Landro A, Cazzaniga S, Cusano F, et al. Adult female acne and associated risk factors: results of a multicenter case-control study in Italy. J Am Acad Dermatol. 2016;75(6):1134–1141.e1.
   PubMed Web of Science ®Google Scholar
• Capitanio B, Sinagra JL, Picardo M. Acne and smoking. Dermatoendocrinol. 2009;1(3):129–135.
   PubMedGoogle Scholar
• Yang YS, Lim HK, Hong KK, et al. Cigarette smoke-induced interleukin-1 alpha may be involved in the pathogenesis of adult acne. Ann Dermatol. 2014;26(1):11–16.
   PubMed Web of Science ®Google Scholar
• Yang J, Tang H, Xu A, et al. A review of advancement on influencing factors of acne: an emphasis on environment characteristics. Front Public Health. 2020;8:450.
   PubMed Web of Science ®Google Scholar
• Dréno B, Bettoli V, Araviiskaia E, et al. The influence of the exposome on acne. J Eur Acad Dermatol Venereol. 2018;30:1–8.
   Web of Science ®Google Scholar
• Dréno B, Shourick J, Kerob D, et al. The role of the exposome in acne: results from an international patient survey. J Eur Acad Dermatol Venereol. 2020;34:1057–1064.
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Evidence for increase androsterone metabolism in some normoandrogenic women with acne. J Clin Endocrinol Metab. 1993;76(5):1111–1114.
   PubMed Web of Science ®Google Scholar
• Slayden SM, Moran C, Sams WM Jr, et al. Hyperandrogenemia in patients presenting with acne. Fertil Steril. 2001;75(5):889–892.
   PubMed Web of Science ®Google Scholar
• Yarak S, Bagatin E, Hassun KM, et al. Hyperandrogenism and skin: polycystic ovary syndrome and insulin peripheral resistance. Brazilian Ann Dermatol. 2005;80(4):395–410.
   Google Scholar
• Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):737–754.
   PubMed Web of Science ®Google Scholar
• Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2014;6:1–13.
   Web of Science ®Google Scholar
• Bansal P, Sardana K, Vats G, et al. A prospective study examining trigger factors and hormonal abnormalities in adult female acne. Indian Dermatol Online J. 2020;11(4):544–550.
   PubMedGoogle Scholar
• Lortscher D, Admani S, Satur N, et al. Hormonal contraceptives and acne: a retrospective analysis of 2147 patients. J Drugs Dermatol. 2016;15(6):670–674.
   PubMed Web of Science ®Google Scholar
• Gezginc K, Balci O, Karatayli R, et al. Contraceptive efficacy and side effects of Implanon. Eur J Contracept Reprod Health Care. 2007;12(4):362–365.
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Brache V, Meirik O, et al. WHO study group on contraceptive implants for women. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod. 2015;30(11):2527–2538.
   PubMed Web of Science ®Google Scholar
• Ferreira MN, Ramseier JY, Leventhal JS. Dermatologic conditions in women receiving systemic cancer therapy. Int J Womens Dermatol. 2019;5(5):285–307.
   PubMedGoogle Scholar
• Preneau S, Dréno B. Female acne - a different subtype of teenager acne? J Eur Acad Dermatol Venereol. 2012;26(3):277–282.
   PubMed Web of Science ®Google Scholar
• Khunger N, Kumar C. A clinico-epidemiological study of adult acne: is it different from adolescent acne? Indian J Dermatol Venereol Leprol. 2012;78(3):335–341.
   PubMed Web of Science ®Google Scholar
• Dréno B, Bagatin E, Blume-Peytavi U, et al. Female type of adult acne: physiological and psychological considerations and management. J Deusch Dermatol Ges. 2018;16(10):1185–1194.
   Web of Science ®Google Scholar
• Rocha M, Cardozo KHM, Carvalho VM, et al. ADT-G as a promising biomarker for peripheral hyperandrogenism in adult female acne. Dermatoendocrinol. 2017;9(1):e1361571.
   PubMed Web of Science ®Google Scholar
• Rocha MAD, Guadanhim LRS, Sanudo A, et al. Modulation of toll like receptor-2 on sebaceous gland by the treatment of adult female acne. Dermatoendocrinol. 2017;9(1):e1361570.
   PubMed Web of Science ®Google Scholar
• Antiga E, Verdelli A, Bonciani D, et al. Acne: a new model of imune-mediated chronic inflammatory skin disease. G Ital Dermatol Venereol. 2015;150:247–254.
   PubMed Web of Science ®Google Scholar
• Rocha MA, Costa CS, Bagatin E. Acne vulgaris: an inflammatory disease even before the onset of clinical lesions. Inflamm Allergy Drug Targets. 2014;13(3):162–167.
   PubMedGoogle Scholar
• Dréno B, Gollnick HPM, Kang S, et al. Understanding innate immunity and inflammation in acne: implications for management. J Eur Acad Dermatol Venereol. 2015;29:3–11.
   PubMed Web of Science ®Google Scholar
• Kim J. Review of the Innate Immune response in acne vulgaris: activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology. 2005;211(3):193–198.
   PubMed Web of Science ®Google Scholar
• O’Neill AM, Gallo RL. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome. 2018;6:177.
   PubMed Web of Science ®Google Scholar
• Gü A, Colgecen E. Personality traits and common psychiatric conditions in adult patients with acne vulgaris. Ann Dermatol. 2015;27(1):48–52.
   PubMed Web of Science ®Google Scholar
• Heng AHS, Chew FT. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020;10:5754.
   PubMed Web of Science ®Google Scholar
• Vallerand IA, Lewinson RT, Parsons LM, et al. Risk of depression among patients with acne in the U.K.: a population-based cohort study. Br J Dermatol. 2018;178(3):e194–e195.
   PubMed Web of Science ®Google Scholar
• Motley RJ, Findlay AY. How much disability is caused by acne? Clin Exp Dermatol. 1989;14:194–198.
   PubMed Web of Science ®Google Scholar
• Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol. 1992;17:1–3.
   PubMed Web of Science ®Google Scholar
• Layton AM, Seukeran D, Cunliffe WJ. Scarred for life? Dermatology. 1997;195(supp 1):15–21.
   PubMedGoogle Scholar
• Gupta M, Johnson AM, Gupta AK. The development of an acne quality of life scale: reliability, validity, and relation to subjective acne severity in mild to moderate acne vulgaris. Acta Derm Venereol. 1998;78:451–456.
   PubMed Web of Science ®Google Scholar
• Girman CJ, Hartmaier S, Thiboutot D, et al. Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. Qual Life Res. 1996;5:481–490.
   PubMed Web of Science ®Google Scholar
• Martin AR, Lookingbill DP, Botek A, et al. Health-related quality of life among patients with facial acne – assessment of a new acne specific questionnaire. Clin Exp Dermatol. 2001;26:380–385.
   PubMed Web of Science ®Google Scholar
• Fehnel SE, McLeod LD, Brandman J, et al. Responsiveness of the acne-specific quality of life questionnaire (Acne- QoL) to treatment for acne vulgaris in placebo-controlled clinical trials. Qual Life Res. 2002;11:809–816.
   PubMed Web of Science ®Google Scholar
• Tan J, Fung KY, Khan S. Condensation and validation of a 4-item index of the Acne-QoL. Qual Life Res. 2006;15:1203–1210.
   PubMed Web of Science ®Google Scholar
• Chernyshov PV, Zouboulis CC, Tomas-Aragones L, et al. Quality of life measurement in acne. position paper of the european academy of dermatology and venereology task forces on quality of life and patient oriented outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol. 2018;32(2):194–208.
   PubMed Web of Science ®Google Scholar
• Gallitano SM, Berson DS. How acne bumps cause the blues: the influence of acne vulgaris on self-esteem. Int J Womens Dermatol. 2018;4(1):12–17.
   PubMedGoogle Scholar
• Davern J, O’Donnell AT. Stigma predicts health-related quality of life impairment, psychological distress, and somatic symptoms in acne sufferers. PLoS One. 2018;13(9):e0205009.
   PubMed Web of Science ®Google Scholar
• Bondade S, Hosthota A, Basavaraju V. Stressful life events and psychiatric comorbidity in a case-control study. Asia Pac Psychiatry. 2019;11(1):e12340.
   PubMed Web of Science ®Google Scholar
• Oztekin C, Oztekin A. The association of depression, loneliness and internet addiction levels in patients with acne vulgaris. Biopsychosoc Med. 2020;14:17.
   PubMed Web of Science ®Google Scholar
• Richter C, Trojahn C, Hilmann K, et al. Sensitivity to change of the dermatology life quality index in adult females with facial acne vulgaris: a validation study. J Eur Acad Dermatol Venereol. 2017;31(1):169–174.
   PubMed Web of Science ®Google Scholar
• Rocha M, Sanudo A, Bagatin E. The effect on acne quality of life of topical azelaic acid 15% gel versus a combined oral contraceptive in adult female acne: a randomized trial. Dermatoendocrinol. 2017;9(1):e1361572.
   PubMedGoogle Scholar
• Albuquerque RG, Rocha MAD, Hirotsu C, et al. A randomized comparative trial of a combined oral contraceptive and azelaic acid to assess their effect on sleep quality in adult female acne patients. Arch Dermatol Res. 2015;307(10):905–915.
   PubMed Web of Science ®Google Scholar
• Clayton RW, Langan EA, Ansell DM, et al. Neuroendocrinology and neurobiology of sebaceous glands. Biol Rev Camb Philos Soc. 2020;95(3):592–624.
   PubMed Web of Science ®Google Scholar
• Taylor MT, Barbieri JS. Depression screening at visits for acne in the United States, 2005-2016. J Am Acad Dermatol. 2020;83(3):936–938.
   PubMed Web of Science ®Google Scholar
• Thiboutot DM, Dréno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the global alliance to improve outcomes in acne. J Am Acad Dermatol. 2018;78(2Suppl 1):S1–S23.e1.
   PubMedGoogle Scholar
• Gold MH, Baldwin H, Lin T. Management of comedonal acne vulgaris with fixed‐combination topical therapy. J Cosmet Dermatol. 2018;17(2):227–231.
   PubMed Web of Science ®Google Scholar
• Tan J, Bissonnette R, Gratton D, et al. The safety and efficacy of four different fixed combination regimens of adapalene 0.1%/benzoyl peroxide 2.5% gel for the treatment of acne vulgaris: results from a randomised controlled study. Eur J Dermatol. 2018;28(4):502–508.
   PubMed Web of Science ®Google Scholar
• Bagatin E, Florez-White M, Arias-Gomez MI, et al. Algorithm for acne treatment - Iberian-Latin American Consensus. Brazilian Ann Dermatol. 2017;92:689–693.
   PubMed Web of Science ®Google Scholar
• Bershad S, Kranjac Singer G, Parente JE, et al. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol. 2002;138:481–489.
   PubMed Web of Science ®Google Scholar
• Levin J. The relationship of proper skin cleansing to pathophysiology, clinical benefits, and the concomitant use of prescription topical therapies in patients with acne vulgaris. Dermatol Clin. 2016;34(2):133–145.
   PubMed Web of Science ®Google Scholar
• Kober MM, Bowe WP. The effects of probiotics on immune regulation, acne and photoaging. Int J Womens Dermatol. 2015;1(2):85–89.
   PubMedGoogle Scholar
• Eichenfield LF, Lain T, Frankel EH, et al. Efficacy and safety of once-daily Dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(8):962–969.
   PubMed Web of Science ®Google Scholar
• Tyring SK, Kircik LH, Pariser DM, et al. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older. J Drugs Dermatol. 2018;17(10):1084–1091.
   PubMed Web of Science ®Google Scholar
• Kircik LH. Anti-inflammatory dose doxycycline plus adapalene 0.3% and benzoyl peroxide 2.5% gel for severe acne. J Drugs Dermatol. 2019;18(9):924–927.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library Of Medicine; cited 2020 Feb 14. Available from: https://clinicaltrials.gov/ct2/show/NCT04214639.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine; cited 2020 Feb 14. Available from: https://clinicaltrials.gov/ct2/show/NCT03653403
   Google Scholar
• Chottawornsak N, Chongpison Y, Asawanonda P, et al. Topical 2% ketoconazole cream monotherapy significantly improves adult female acne: a double-blind, randomized placebo-controlled trial. J Dermatol. 2019;46(12):1184–1189.
   PubMed Web of Science ®Google Scholar
• Raoof TJ, Hooper D, Moore A, et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: a phase 3 study. J Am Acad Dermatol. 2020;82(4):832–837.
   PubMed Web of Science ®Google Scholar
• Blume-Peytavi U, Fowler J, Keme´ny L, et al. Longterm safety and efficacy of trifarotene 50 lg/g cream, a first-in-class RAR-c selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020;34(1):166–173.
   PubMed Web of Science ®Google Scholar
• Tanghetti EA, Werschler WP, Lain T, et al. Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials. J Drugs Dermatol. 2020;19(1):70–77.
   PubMed Web of Science ®Google Scholar
• Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(6):621–630.
   PubMed Web of Science ®Google Scholar
• Barbieri JS. A new class of topical acne treatment addressing the hormonal pathogenesis of acne. JAMA Dermatol. 2020;156(6):619–620.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Hekmatjah J, Kircik LH. Oral tetracyclines and acne: a systematic review for dermatologists. J Drugs Dermatol. 2020;19(11):s6–s13.
   PubMed Web of Science ®Google Scholar
• Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant?: implications of resistance for acne patients and prescribers. Am J Clin Dermatol. 2003;4(12):813–831.
   PubMed Web of Science ®Google Scholar
• Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–73.e33. Erratum in: J Am Acad Dermatol. 2020;82(6):1576.
   PubMed Web of Science ®Google Scholar
• Bagatin E, Freitas THP, Rivitti-Machado MC, et al. Adult female acne: a guide to clinical practice. Brazilian Ann Dermatol. 2019;94(1):62–75.
   PubMed Web of Science ®Google Scholar
• Nast A, Dréno B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol. 2016;30(8):1261–1268.
   PubMed Web of Science ®Google Scholar
• Ozolins M, Eady EA, Avery AJ, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet. 2004;364:2188–2195.
   PubMed Web of Science ®Google Scholar
• Tzellos T, Zampeli V, Makrantonaki E, et al. Treating acne with antibiotic-resistant bacterial colonization. Expert Opin Pharmacother. 2011;12(8):1233–1247.
   PubMed Web of Science ®Google Scholar
• Bienenfeld A, Nagler AR, Orlow SJ. Oral antibacterial therapy for acne vulgaris: an evidence-based review. Am J Clin Dermatol. 2017;18(4):469–490.
   PubMed Web of Science ®Google Scholar
• Shaw JC, White LE. Persistent acne in adult women. Arch Dermatol. 2001;137(9):1252–1253.
   PubMedGoogle Scholar
• Sardana K, Mathachan SR, Gupta T. Antibiotic resistance in acne an emergent need to recognize resistance to azithromycin and restrict its unapproved use in acne vulgaris. J Eur Acad Dermatol Venereol. 2020 Dec 22; DOI:10.1111/jdv.17099
   Web of Science ®Google Scholar
• Garner SE, Eady A, Bennett C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012;2012(8):CD002086.
   Google Scholar
• Ochsendorf F. Systemic antibiotic therapy of acne vulgaris. J Dtsch Dermatol Ges. 2010;8(Suppl 1):S31–46.
   PubMedGoogle Scholar
• Leyden JJ, Sniukiene V, Berk DR, et al. Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study. J Drugs Dermatol. 2018;17(3):333–338.
   PubMed Web of Science ®Google Scholar
• Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol. 2018;17(9):987–996.
   PubMed Web of Science ®Google Scholar
• Kircik LH. ARTICLE: a novel antibiotic just for acne. J Drugs Dermatol. 2020;19(11):s5.
   PubMed Web of Science ®Google Scholar
• Chernyshov PV, Tomas-Aragones L, Manolache L, et al. Which acne treatment has the best influence on health-related quality of life? Literature review by the European academy of dermatology and venereology task force on quality of life and patient oriented outcomes. J Eur Acad Dermatol Venereol. 2018;32(9):1410–1419.
   PubMed Web of Science ®Google Scholar
• Bagatin E, Costa CS. The use of isotretinoin for acne - an update on optimal dosing, surveillance, and adverse effects. Expert Rev Clin Pharmacol. 2020;13(8):885–897.
   PubMed Web of Science ®Google Scholar
• Törmä H. Regulation of keratin expression by retinoids. Dermatoendocrinol. 2011;3(3):136–140.
   PubMedGoogle Scholar
• Chen W, Zhao S, Zhu W, et al. Retinoids as an immunity-modulator in Dermatology disorders. Arch Immunol Ther Exp (Warsz). 2019;67:355–365.
   PubMed Web of Science ®Google Scholar
• Dispenza MC, Wolpert EB, Gilliland KL, et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2 mediated innate immune responses in acne patients. J Invest Dermatol. 2012;132(9):2198–2205.
   PubMed Web of Science ®Google Scholar
• Melnik BC. Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity. Acta Derm Venereol. 2017;97(2):173–181.
   PubMed Web of Science ®Google Scholar
• Ganceviciene R, Zouboulis CC. Isotretinoin: state of the art treatment for acne vulgaris. J Dtsch Dermatol Ges. 2010;8(Suppl 1):S47–59.
   PubMedGoogle Scholar
• Mccoy WH 4th, Otchere E, Rosa BA, et al. Skin ecology during sebaceous drought-how skin microbes respond to isotretinoin. J Invest Dermatol. 2019;139(3):723–735.
   PubMed Web of Science ®Google Scholar
• RocheRoacutan (isotretinoína) Produtos Roche Químicos e Farmacêuticos S.A Available from: http://www.anvisa.gov.br/datavisa/filabula/frmVisualizarBula.asp?pNuTransacao=14365632016&pIdAnexo=3212245
   Google Scholar
• Costa CS, Bagatin E, Martimbianco ALC, et al. Oral isotretinoin for acne. Cochrane Database Syst Rev. 2018;11(11):CD009435. Tan J, Knezevic S, Boyal S, et al. Evaluation of evidence for acne remission with oral isotretinoin cumulative dosing of 120-150mg/kg. J Cutan Med Surg. 2016;20(1):13-20
   PubMedGoogle Scholar
• Tan J, Boyal S, Desai K, et al. Oral Isotretinoin: new developments relevant to clinical practice. Dermatol Clin. 2016;34:175–184.
   PubMed Web of Science ®Google Scholar
• Rademaker M. Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris. Int J Dermatol. 2016;55(5):518-523.
   PubMed Web of Science ®Google Scholar
• Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1(3):162–169.
   PubMedGoogle Scholar
• Fallah H, Rademaker M. Isotretinoin in the management of acne vulgaris: practical prescribing. Int J Dermatol. 2020 Aug 29; DOI:10.1111/ijd.15089
   PubMed Web of Science ®Google Scholar
• Webster GF, Leyden JJ, Gross JA. Results of a phase 1152 III, double-blind, randomized, parallel-group, non-inferiority 1153 study evaluating the safety and efficacy of isotretinoin-Lidose 1154 in patients with severe recalcitrant nodular acne. J Drugs Dermatol. 2014;13:665–670.
   PubMed Web of Science ®Google Scholar
• Brito MF, Sant’Anna IP, Galindo JC, et al. Evaluation of clinical adverse effects and laboratory alterations in patients with acne vulgaris treated with oral isotretinoin. Brazilian Ann Dermatol. 2010;85(3):331–337.
   PubMed Web of Science ®Google Scholar
• Vallerand IA, Lewinson RT, Farris MS, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2018;178(1):76–85.
   PubMed Web of Science ®Google Scholar
• Altman RS, Altman LJ, Altman JS. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology. 2002;204(3):232–235.
   PubMed Web of Science ®Google Scholar
• Lee YH, Scharnitz TP, Muscat J, et al. Laboratory monitoring during isotretinoin therapy for acne: a systematic review and meta-analysis. JAMA Dermatol. 2016;152(1):35–44. Erratum in: JAMA Dermatol. 2016;152(1):114
   PubMed Web of Science ®Google Scholar
• Barth JH, Macdonald-Hull SP, Mark J, et al. Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol. 1993;129(6):704–707.
   PubMed Web of Science ®Google Scholar
• Nau H. Teratogenicity of isotretinoin revisited: species variation and the role of all-trans-retinoic acid. J Am Acad Dermatol. 2001;45:S183–187.
   PubMed Web of Science ®Google Scholar
• Oztürk S, Oztürk T, Ucak H, et al. Evaluation of ovarian reserve and function in female patients treated with oral isotretinoin for severe acne: an exploratory study. Cutan Ocul Toxicol. 2015;34(1):21–24.
   PubMed Web of Science ®Google Scholar
• Cinar SL, Kartal D, Aksoy H, et al. Long-term effect of systemic isotretinoin on female fertility. Cutan Ocular Toxicol. 2017;36(2):132–134.
   PubMed Web of Science ®Google Scholar
• Etminan M, Bird ST, Delaney JA, et al. Isotretinoin and risk for inflammatory bowel disease: a nested 1250 case-control study and meta-analysis of published and unpublished data. JAMA Dermatol. 2013;149:216–220.
   Google Scholar
• Lee SY, Jamal MM, Nguyen ET, et al. Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis. Eur J Gastroenterol Hepatol. 2016;28:210–216.
   PubMed Web of Science ®Google Scholar
• Margolis DJ, Fanelli M, Hoffstad O, et al. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol. 2010;105(12):2610–2616.
   PubMed Web of Science ®Google Scholar
• Wright S, Strunk A, Garg A. Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin. J Am Acad Dermatol. 2021;84(1):41–45.
   PubMed Web of Science ®Google Scholar
• Singer S, Tkachenko E, Sharma P, et al. Psychiatric adverse events in patients taking isotretinoin as reported in a food and drug administration database from 1997 to 2017. JAMA Dermatol. 2019;155(10):1162–1166.
   PubMed Web of Science ®Google Scholar
• Huang YC, Cheng YC. Use of isotretinoin and risk of depression in patients with acne: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;76:1068–1076.
   PubMed Web of Science ®Google Scholar
• Borghi A, Mantovani L, Minghetti S, et al. Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission. J Eur Acad Dermatol Venereol. 2011;25(9):1094–1098.
   PubMed Web of Science ®Google Scholar
• Rademaker M, Wishart JM, Birchall NM. Isotretinoin 5mg daily for low-grade adult acne vulgaris - a placebo-controlled, randomized double-blind study. J Eur Acad Dermatol Venereol. 2014;28:747–754.
   PubMed Web of Science ®Google Scholar
• Bagatin E, Costa CS, Rocha MADD, et al. Consensus on the use of oral isotretinoin in dermatology - Brazilian society of dermatology. Brazilian Ann Dermatol. 2020;95 Suppl 1(Suppl1):19–38.
   PubMedGoogle Scholar
• Spring LK, Krakowski AC, Alam M, et al. Isotretinoin and timing of procedural interventions: a systematic review with consensus recommendations. JAMA Dermatol. 2017;153(8):802–809.
   PubMed Web of Science ®Google Scholar
• Waldman A, Bolotin D, Arndt KA, et al. ASDS guidelines task force: consensus recommendations regarding the safety of lasers, dermabrasion, chemical peels, energy devices, and skin surgery during and after isotretinoin use. Dermatol Surg. 2017;43(10):1249–1262.
   PubMed Web of Science ®Google Scholar
• McDonald KA, Shelley AJ, Pierscianowski T, et al. A 2017 update: challenging the cosmetic procedural delay following oral isotreti- noin therapy. J Cosmet Laser Ther. 2019;21:58–60.
   PubMed Web of Science ®Google Scholar
• Chandrashekar BS, Varsha DV, Vasanth V. Safety of performing invasive acne scar treatment and laser hair removal in patients on oral isotretinoin: a retrospective study of 110 patients. Int J Dermatol. 2014;53(10):1281–1285.
   PubMed Web of Science ®Google Scholar
• Khatri KA, Iqbal N, Bhawan J. Laser skin resurfacing during isotretinoin therapy. Dermatol Surg. 2015;41(6):758–759.
   PubMed Web of Science ®Google Scholar
• Guadanhim LR, Gonçalves RG, Bagatin E. Observational retrospective study evaluating the effects of oral isotretinoin in keloids and hypertrophic scars. Int J Dermatol. 2016;55:1255–1258.
   PubMed Web of Science ®Google Scholar
• Picosse FR, Yarak S, Cabral NC, et al. Early chemabrasion for acne scars after treatment with oral isotretinoin. Dermatol Surg. 2012;38(9):1521–1526.
   PubMed Web of Science ®Google Scholar
• Saluja SS, Walker ML, Summers EM, et al. Safety of non-ablative fractional laser for acne scars within 1 month after treatment with oral isotretinoin: a randomized split-face controlled trial. Lasers Surg Med. 2017;49(10):886–890.
   PubMed Web of Science ®Google Scholar
• Xia J, Hu G, Hu D, et al. Concomitant use of 1,550-nm nonablative fractional laser with low-dose isotretinoin for the treatment of acne vulgaris in Asian patients: a randomized split-face controlled study. Dermatol Surg. 2018;44(9):1201–1208.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Park EJ, Kwon IH, et al. Concomitant use of an infrared fractional laser with low-dose Isotretinoin for the treatment of acne and acne scars. J Dermatolog Treat. 2014;25:142–146.
   PubMed Web of Science ®Google Scholar
• Labrie F, Martel C, Bélanger A, et al. Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology. J Steroid Biochem Mol Biol. 2017;168:9–18.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol. 2004;22(5):360–366.
   PubMed Web of Science ®Google Scholar
• Van Vloten WA, Van Haselen CW, Van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69(4):2–15.
   PubMedGoogle Scholar
• Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997;89(4):615–622.
   PubMed Web of Science ®Google Scholar
• Maloney JM, Dietze P Jr, Watson D, et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol. 2008;112(4):773–781.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC. Sebaceous gland receptors. Dermatoendocrinol. 2009;1(2):77–80.
   PubMedGoogle Scholar
• Golobof A, Kiley J. The current status of oral contraceptives: progress and recent innovations. Semin Reprod Med. 2016;34(3):145–151.
   PubMed Web of Science ®Google Scholar
• Lemay A, Dewailly SD, Grenier R, et al. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel. J Clin Endocrinol Metab. 1990;71(1):8–14.
   PubMed Web of Science ®Google Scholar
• Barbieri JS, Mitra N, Margolis DJ, et al. Influence of contraception class on incidence and severity of acne vulgaris. Obstet Gynecol. 2020;135(6):1306–1312.
   PubMed Web of Science ®Google Scholar
• Bosanac SS, Trivedi M, Clark AK, et al. Progestins and acne vulgaris: a review. Dermatol Online J. 2018;24(5):13030/qt6wm945xf.
   Google Scholar
• Koo EB, Petersen TD, Kimball AB. Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. J Am Acad Dermatol. 2014;71(3):450–459.
   PubMed Web of Science ®Google Scholar
• Arowojolu AO, Gallo MF, Lopez LM, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;7:CD004425.
   PubMedGoogle Scholar
• Raymond EG, Burke AE, Espey E. Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective. Obstet Gynecol. 2012;119(5):1039–1044.
   PubMed Web of Science ®Google Scholar
• Dréno B, Bettoli V, Ochsendorf F, et al. European expert group on oral antibiotics in acne. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004;14(6):391–399.
   PubMed Web of Science ®Google Scholar
• Akamatsu H, Zouboulis CC, Orfanos CE. Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5α-dihydrotestosterone in vitro. J Invest Dermatol. 1993;100(5):660–662.
   PubMed Web of Science ®Google Scholar
• Layton AM, Eady EA, Whitehouse H, et al. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol. 2017;18(2):169–191.
   PubMed Web of Science ®Google Scholar
• Helfer EL, Miller JL, Rose LI. Side-effects of spironolactone therapy in the hirsute woman. J Clin Endocrinol Metab. 1988;66(1):208–211.
   PubMed Web of Science ®Google Scholar
• Wolverton SE, Wu JJ. Comprehensive dermatologic drug therapy. 4th ed. Amsterdam, Netherlands: Elsevier; 2021. p. 858p.
   Google Scholar
• Lainscak M, Pelliccia F, Rosano G, et al. Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol. 2015;200:25–29.
   PubMed Web of Science ®Google Scholar
• Charny JW, Choi JK, James WD. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. Int J Womens Dermatol. 2017;3(2):111–115.
   PubMedGoogle Scholar
• American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 1994;93:137–150.
   PubMed Web of Science ®Google Scholar
• Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43(3):498–502.
   PubMed Web of Science ®Google Scholar
• Barbieri JS, Choi JK, James WD, et al. Real-world drug usage survival of spironolactone versus oral antibiotics for the management of female patients with acne. J Am Acad Dermatol. 2019;81(3):848–851.
   PubMed Web of Science ®Google Scholar
• Roberts EE, Nowsheen S, Davis MDP, et al. Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017. J Eur Acad Dermatol Venereol. 2020;34(9):2106–2110.
   PubMed Web of Science ®Google Scholar
• Gainder S, Sharma B. Update on management of polycystic ovarian syndrome for dermatologists. Indian Dermatol Online J. 2019;10(2):97–105.
   PubMedGoogle Scholar
• Cyproterone Article-31 referral - Restrictions in use of cyproterone due to meningioma risk. Last updated: 20/05/2020 EMA/147755/2020.
   Google Scholar
• Kim GK, Del Rosso JQ. Oral Spironolactone in post-teenage female patients with acne vulgaris: practical considerations for the clinician based on current data and clinical experience. J Clin Aesthet Dermatol. 2012;5(3):37–50.
   PubMedGoogle Scholar
• De Melo AS, Dos Reis RM, Ferriani RA, et al. Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits. Open Access J Contracept. 2017;8:13–23.
   PubMed Web of Science ®Google Scholar
• Dréno B, Araviiskaia E, Kerob D, et al. Nonprescription acne vulgaris treatments: their role in our treatment armamentarium - an international panel discussion. J Cosmet Dermatol. 2020;19(9):2201–2211.
   PubMed Web of Science ®Google Scholar
• Thiboutot D, Del Rosso JQ. Acne vulgaris and the epidermal barrier: is acne vulgaris associated with inherent epidermal abnormalities that cause impairment of barrier functions? Do any topical acne therapies alter the structural and/or functional integrity of the epidermal barrier? J Clin Aesthet Dermatol. 2013;6(2):18–24.
   PubMedGoogle Scholar
• Decker A, Graber EM. Over-the-counter acne treatments: a review. J Clin Aesth Dermatol. 2012;5:32–40.
   PubMedGoogle Scholar
• Del Rosso JQ. The role of skin care as an integral component in the management of acne vulgaris: part 1: the importance of cleanser and moisturizer ingredients, design, and product selection. J Clin Aesthet Dermatol. 2013;6(12):19–27.
   PubMedGoogle Scholar
• Araviiskaia E, Dréno B. The role of dermocosmetics in acne vulgaris. J Eur Acad Dermatol Venereol. 2016;30:926–935.
   PubMed Web of Science ®Google Scholar
• Bagatin E, Holzmann R, Shakery K, et al. Adult female acne. Azelaic acid in the treatment of acne in adult female. Skin Pharmacol Physiol. 2014;27(Suppl 1):1–2.
   PubMedGoogle Scholar
• Schorr ES, Sidou F, Kerrouche N. Adjunctive use of a facial moisturizer SPF 30 containing ceramide precursor improves the tolerability of topical tretinoin 0.05%: a randomized, investigator-blinded, split face study. J Drugs Dermatol. 2012;11(9):1104–1107.
   PubMed Web of Science ®Google Scholar
• Isoda K, Seki T, Inoue Y, et al. Efficacy of the combined use of a facial cleanser and moisturizers for the care of mild acne patients with sensitive skin. J Dermatol. 2015;42(2):181–188.
   PubMed Web of Science ®Google Scholar
• Lynde CW, Andriessen A, Barankin B, et al. Moisturizers and ceramide-containing moisturizers may offer concomitant therapy with benefits. J Clin Aesthet Dermatol. 2014;7(3):18–26.
   PubMedGoogle Scholar
• Rocha MA, Bagatin E. Skin barrier and microbiome in acne. Arch Dermatol Res. 2018;310(3):181–185.
   PubMed Web of Science ®Google Scholar
• Barbaric J, Abbott R, Posadzki P, et al. Light therapies for acne. Cochrane Database Syst Rev. 2016;9(9):CD007917.
   PubMedGoogle Scholar
• Celasco G, Moro L, Bozzella R, et al. Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung. 2004;54(12):881–886.
   PubMed Web of Science ®Google Scholar
• Trifu V, Tiplica GS, Naumescu E, et al. Cortexolone 17alphapropionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. Br J Dermatol. 2011;165(1):177–183.
   PubMed Web of Science ®Google Scholar
• Han JJ, Falestsky A, Barbieri JS, et al. New acne therapies and updates on use of spironolactone and isotretinoin: a narrative. review. Dermatol Ther (Heidelb). 2021; DOI:10.1007/s13555-020-00481-w.
   Web of Science ®Google Scholar
• Eichenfield LF, Hebert A, Gold LS, et al. Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris. J Am Acad Dermatol. 2020;83(2):477–485.
   PubMed Web of Science ®Google Scholar
• Müderris II, Bayram F, Ozçelik B, et al. New alternative treatment in hirsutism: bicalutamide 25 mg/day. Gynecol Endocrinol. 2002;16(1):63–66.
   PubMed Web of Science ®Google Scholar
• Moretti C, Guccione L, Di Giacinto P, et al. Combined oral contraception and bicalutamide in polycystic ovary syndrome and severe hirsutism: a double-blind randomized controlled trial. J Clin Endocrinol Metab. 2018;103(3):824–838.
   PubMed Web of Science ®Google Scholar
• Fernandez-Nieto D, Saceda-Corralo D, Rodrigues-Barata R, et al. Oral bicalutamide for female pattern hair loss: a pilot study. Dermatol Ther. 2019;32(6):e13096.
   PubMed Web of Science ®Google Scholar
• Trivedi MK, Bosanac SS, Sivamani R, et al. Emerging therapies for acne vulgaris. Am J Clin Dermatol. 2018;19(4):505–516.
   PubMed Web of Science ®Google Scholar